Cost-effectiveness of community-based household tuberculosis contact management for children in Cameroon and Uganda: a modelling analysis of a cluster-randomised trial
View/ Open
Date
2023Author
Mafirakureva, Nyashadzaishe
Tchounga, Boris K
Mukherjee, Sushant
Youngui, Boris Tchakounte
Ssekyanzi, Bob
Simo, Leonie
Okello, Richard F
Turyahabwe, Stavia
Kuate, Albert Kuate
Cohn, Jennifer
Vasiliu, Anca
Casenghi, Martina
Atwine, Daniel
Bonnet, Maryline
Dodd, Peter J
Metadata
Show full item recordAbstract
Background: WHO recommends household contact management (HCM) including contact screening and tuberculosis preventive treatment (TPT) for eligible children. The CONTACT trial found increased TPT initiation and completion rates when community health workers were used for HCM in Cameroon and Uganda.
Methods: We did a cost–utility analysis of the CONTACT trial using a health-system perspective to estimate the health impact, health-system costs, and cost-effectiveness of community-based versus facility-based HCM models of care. A decision-analytical modelling approach was used to evaluate the cost-effectiveness of the intervention compared with the standard of care using trial data on cascade of care, intervention effects, and resource use. Health outcomes were based on modelled progression to tuberculosis, mortality, and discounted disability-adjusted life-years (DALYs) averted. Health-care resource use, outcomes, costs (2021 US$), and cost-effectiveness are presented.
Findings: For every 1000 index patients diagnosed with tuberculosis, the intervention increased the number of TPT courses by 1110 (95% uncertainty interval 894 to 1227) in Cameroon and by 1078 (796 to 1220) in Uganda compared with the control model. The intervention prevented 15 (–3 to 49) tuberculosis deaths in Cameroon and 10 (–20 to 33) in Uganda. The incremental cost-effectiveness ratio was $620 per DALY averted in Cameroon and $970 per DALY averted in Uganda.
Interpretation: Community-based HCM approaches can substantially reduce child tuberculosis deaths and in our case would be considered cost-effective at willingness-to-pay thresholds of $1000 per DALY averted. Their impact and cost-effectiveness are likely to be greatest where baseline HCM coverage is lowest
Collections
- Research Article [117]